These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 36168623

  • 1. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
    Kuo HT, Lin KS, Zhang Z, Zhang C, Merkens H, Tan R, Roxin A, Uribe CF, Bénard F.
    Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
    [Abstract] [Full Text] [Related]

  • 2. Lys-urea-Aad, Lys-urea-Cmc and Lys-urea-Cms as potential pharmacophores for the design of PSMA-targeted radioligands to reduce off-target uptake in kidneys and salivary glands.
    Kuo HT, Zhang Z, Zhang C, Merkens H, Tan R, Wong AAWL, Uribe CF, Bénard F, Lin KS.
    Theranostics; 2023; 13(13):4559-4573. PubMed ID: 37649602
    [Abstract] [Full Text] [Related]

  • 3. 177Lu-Labeled Albumin-Binder-Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio.
    Kuo HT, Lin KS, Zhang Z, Uribe CF, Merkens H, Zhang C, Bénard F.
    J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704
    [Abstract] [Full Text] [Related]

  • 4. Enhancing Treatment Efficacy of 177Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies.
    Kuo HT, Merkens H, Zhang Z, Uribe CF, Lau J, Zhang C, Colpo N, Lin KS, Bénard F.
    Mol Pharm; 2018 Nov 05; 15(11):5183-5191. PubMed ID: 30251544
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and evaluation of a novel urea-based 68Ga-complex for imaging PSMA binding in tumor.
    Zha Z, Ploessl K, Choi SR, Wu Z, Zhu L, Kung HF.
    Nucl Med Biol; 2018 Apr 05; 59():36-47. PubMed ID: 29459281
    [Abstract] [Full Text] [Related]

  • 6. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M, Umbricht CA, Schibli R, Müller C.
    Mol Pharm; 2018 Mar 05; 15(3):934-946. PubMed ID: 29400475
    [Abstract] [Full Text] [Related]

  • 7. Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer.
    Eppard E, de la Fuente A, Benešová M, Khawar A, Bundschuh RA, Gärtner FC, Kreppel B, Kopka K, Essler M, Rösch F.
    Theranostics; 2017 Mar 05; 7(18):4359-4369. PubMed ID: 29158832
    [Abstract] [Full Text] [Related]

  • 8. Improve the Biodistribution with Bulky and Lipophilic Modification Strategies on Lys-Urea-Glu-Based PSMA-Targeting Radiotracers.
    Cai P, Tang S, Xia L, Wang Y, Liu Y, Feng Y, Liu N, Chen Y, Zhou Z.
    Mol Pharm; 2023 Feb 06; 20(2):1435-1446. PubMed ID: 36696174
    [Abstract] [Full Text] [Related]

  • 9. Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T.
    Yusufi N, Wurzer A, Herz M, D'Alessandria C, Feuerecker B, Weber W, Wester HJ, Nekolla S, Eiber M.
    J Nucl Med; 2021 Aug 01; 62(8):1106-1111. PubMed ID: 33443072
    [Abstract] [Full Text] [Related]

  • 10. Synthesis and Evaluation of 99mTc-Labeled PSMA-Targeted Tracers Based on the Lys-Urea-Aad Pharmacophore for Detecting Prostate Cancer with Single Photon Emission Computed Tomography.
    Lu K, Zhang C, Zhang Z, Kuo HT, Colpo N, Bénard F, Lin KS.
    Molecules; 2023 Jun 29; 28(13):. PubMed ID: 37446782
    [Abstract] [Full Text] [Related]

  • 11. Effects of Linker Modification on Tumor-to-Kidney Contrast of 68Ga-Labeled PSMA-Targeted Imaging Probes.
    Kuo HT, Pan J, Zhang Z, Lau J, Merkens H, Zhang C, Colpo N, Lin KS, Bénard F.
    Mol Pharm; 2018 Aug 06; 15(8):3502-3511. PubMed ID: 29920108
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and Evaluation of 68Ga- and 177Lu-Labeled (R)- vs (S)-DOTAGA Prostate-Specific Membrane Antigen-Targeting Derivatives.
    Zhao R, Ploessl K, Zha Z, Choi S, Alexoff D, Zhu L, Kung HF.
    Mol Pharm; 2020 Dec 07; 17(12):4589-4602. PubMed ID: 33108189
    [Abstract] [Full Text] [Related]

  • 13. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
    Kelly JM, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C, DiMagno SG, Babich JW.
    J Nucl Med; 2019 May 07; 60(5):656-663. PubMed ID: 30552199
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
    Schottelius M, Wurzer A, Wissmiller K, Beck R, Koch M, Gorpas D, Notni J, Buckle T, van Oosterom MN, Steiger K, Ntziachristos V, Schwaiger M, van Leeuwen FWB, Wester HJ.
    J Nucl Med; 2019 Jan 07; 60(1):71-78. PubMed ID: 30237214
    [Abstract] [Full Text] [Related]

  • 15. Monosodium Glutamate Reduces 68Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model.
    Rousseau E, Lau J, Kuo HT, Zhang Z, Merkens H, Hundal-Jabal N, Colpo N, Lin KS, Bénard F.
    J Nucl Med; 2018 Dec 07; 59(12):1865-1868. PubMed ID: 30097503
    [Abstract] [Full Text] [Related]

  • 16. Novel [68Ga/177Lu]Ga/Lu-AZ-093 as PSMA-Targeting Agent for Diagnosis and Radiotherapy.
    Wang R, Jin W, Luo Y, Hong H, Zhao R, Li L, Yan L, Qiao J, Ploessl K, Zhu L, Kung HF.
    Mol Pharm; 2024 Jul 01; 21(7):3256-3267. PubMed ID: 38856975
    [Abstract] [Full Text] [Related]

  • 17. (R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.
    Gourni E, Canovas C, Goncalves V, Denat F, Meyer PT, Maecke HR.
    PLoS One; 2015 Jul 01; 10(12):e0145755. PubMed ID: 26700033
    [Abstract] [Full Text] [Related]

  • 18. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors.
    Kelly J, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C, Schlyer D, Zhao Y, Kim D, Babich JW.
    Eur J Nucl Med Mol Imaging; 2018 Oct 01; 45(11):1841-1851. PubMed ID: 29623376
    [Abstract] [Full Text] [Related]

  • 19. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA, Benešová M, Schibli R, Müller C.
    Mol Pharm; 2018 Jun 04; 15(6):2297-2306. PubMed ID: 29684274
    [Abstract] [Full Text] [Related]

  • 20. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
    Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, Eisenhut M, Kübler W, Holland-Letz T, Giesel FL, Mier W, Kopka K, Haberkorn U.
    J Nucl Med; 2015 Nov 04; 56(11):1697-705. PubMed ID: 26294298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.